Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04852354 · ClinicalTrials.gov registry record
Tissue Collection for Drug Screening and Bioanalysis
A clinical trial of Central Nervous System Tumor, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04852354 is a study of Central Nervous System Tumor that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 500 participants, above the 82-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (510% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04852354, a study of Central Nervous System Tumor, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to test how they respond to different drugs. This research will help improve treatment options and identify new targets for therapy.
Conditions Studied
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2029-07-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04852354
The ClinicalTrials.gov registry entry for NCT04852354 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (510% higher). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT04852354 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04852354 about?
NCT04852354 is a clinical study titled "Tissue Collection for Drug Screening and Bioanalysis". The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to te...
What is the current status of trial NCT04852354?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-07-22. Estimated completion is 2029-07-22.
What conditions does trial NCT04852354 study?
This clinical trial studies the following conditions: Central Nervous System Tumor.
Who is sponsoring clinical trial NCT04852354?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04852354 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Slice Explants to Predict Drug Response in Brain Tumors
RECRUITING
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RECRUITING · Phase 1
-
Somatic Mosaicism in Twins Discordant for Childhood Cancer
RECRUITING
-
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.